4-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-phenylamine | 862665-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 4-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-phenylamine
• 英文别名: 4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)phenylamine；4-(1,4-diazabicyclo[3.2.2]nonan-4-yl)aniline
• CAS: 862665-47-2
• 化学式: C₁₃H₁₉N₃
• 分子量: 217.314
• InChiKey: UHIALSCGSLKFJO-UHFFFAOYSA-N

物化性质

• 沸点：
  397.5±27.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-phenylamine 、 2-硝基苯甲酰氯 以 乙二醇二甲醚 为溶剂， 反应 15.0h， 以54%的产率得到N-[4-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-2-nitro-benzamide
  参考文献：
  名称：

  [EN] NOVEL DIAZA-BICYCLONONYL-PHENYL DERIVATIVES AND THEIR MEDICAL USE
  [FR] NOUVEAUX DÉRIVÉS DE DIAZA-BICYCLONONYL-PHÉNYLE ET LEURS APPLICATIONS MÉDICALES

  摘要：

  这项发明涉及新型的二氮杂双环壬基苯衍生物及其在制造药物组合物中的应用。本发明的化合物被发现是胆碱能受体的胆碱能配体，同时也是单胺受体和转运体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩有关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，炎症有关的疾病或障碍，疼痛以及由滥用化学物质终止而引起的戒断症状等多种疾病或障碍具有用处。

  公开号：

  WO2010063784A1
• 作为产物：
  描述：

  4-(4-nitro-phenyl)-1,4-diaza-bicyclo[3.2.2]nonane 在 钯 氢气 、 crude mixture 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成 4-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-phenylamine
  参考文献：
  名称：

  Diazabicyclic aryl derivatives as cholinergic receptor modulators

  摘要：

  本发明涉及一种新型的二氮杂双环芳基衍生物，发现它们是乙酰胆碱受体的胆碱能配体和单胺类受体和转运体的调节剂。由于它们的药理特性，该发明的化合物可能对治疗与中枢神经系统（CNS）、外周神经系统（PNS）、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及因化学物质滥用终止而引起的戒断症状等多种疾病或障碍具有用处。

  公开号：

  US07662808B2

文献信息

• BMP-SIGNAL-INHIBITING COMPOUND
  申请人：RIKEN

  公开号：US20190337926A1

  公开（公告）日：2019-11-07

  The present invention relates to novel and excellent small-molecule-corn pounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

  本发明涉及一种新颖且优秀的小分子化合物，可以特异性拮抗BMP信号通路，这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或病理症状，包括炎症、心血管疾病、造血系统疾病、癌症、骨发育不良等，特别是纤维性骨化进行性疾病。本发明涉及提供一种用于特异性拮抗BMP信号通路并作用于BMP信号通路的药物和药理剂，用于预防和治疗或实验应用，因为这些化合物有助于调节细胞分化和/或细胞增殖。
• [EN] DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS<br/>[FR] DERIVES D'ARYLE DIAZABICYCLIQUES CONSTITUANT DES MODULATEURS DES RECEPTEURS CHOLINERGIQUES
  申请人：NEUROSEARCH AS

  公开号：WO2005074940A1

  公开（公告）日：2005-08-18

  This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemicals substances.

  这项发明涉及新型的二氮杂双环芳基衍生物，发现它们在尼古丁乙酰胆碱受体上是胆碱能配体，并且调节单胺受体和转运体。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及由于滥用化学物质而导致的戒断症状等多种疾病或障碍具有用处。
• Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators
  申请人：Peters Dan

  公开号：US20080227773A1

  公开（公告）日：2008-09-18

  This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemicals substances.

  本发明涉及新型的二氮杂双环芳基衍生物，这些衍生物被发现是乙酰胆碱受体的胆碱能配体，以及单胺类受体和转运体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或障碍，平滑肌收缩相关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，炎症、疼痛以及因滥用化学物质的终止而引起的戒断症状等多种疾病或障碍具有用处。
• DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS
  申请人：PETERS Dan

  公开号：US20100113428A1

  公开（公告）日：2010-05-06

  This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的二氮杂双环芳基衍生物，其在尼古丁酸乙酰胆碱受体上被发现为胆碱能配体，并且是单胺类受体和转运体的调节剂。由于它们的药理学特性，本发明的化合物可能有用于治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛以及化学物质滥用终止引起的戒断症状等多种疾病或障碍的治疗。
• NOVEL DIAZA-BICYCLONONYL-PHENYL DERIVATIVES AND THEIR MEDICAL USE
  申请人：Peters Dan

  公开号：US20110257161A1

  公开（公告）日：2011-10-20

  This invention relates to novel diazabicyclononyl-phenyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型二氮杂双环壬基苯基衍生物及其在制备药物组成物方面的应用。本发明的化合物被发现是尼古丁乙酰胆碱受体的胆碱能配体和单胺类受体和转运体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统(CNS)的胆碱能系统、外周神经系统(PNS)、平滑肌收缩有关的疾病或紊乱、内分泌疾病或紊乱、神经退行性疾病或紊乱、炎症、疼痛和由于滥用化学物质的终止而引起的戒断症状等多种疾病或紊乱具有用处。